Dimethylaminoparthenolide reduces the incidence of dysplasia and ameliorates a wasting syndrome in HPV16‐transgenic mice
- 13 July 2019
- journal article
- research article
- Published by Wiley in Drug Development Research
- Vol. 80 (6) , 824-830
Abstract
The nuclear factor kappa light chain enhancer of activated B cells (NF-κB) has been implicated in the progression of cancers induced by high-risk human papillomaviruses (HPV). In cancer patients, NF-κB is also thought to drive a chronic systemic inflammatory status, leading to cachexia. This study addressed the ability of dimethylaminoparthenolide (DMAPT), a water-soluble NF-κB inhibitor, to block the development of HPV-induced lesions and wasting syndrome in HPV16-transgenic mice. Mice received DMAPT orally (100 mg/kg/day), once a day, for 6 consecutive weeks. Body weight was monitored weekly along with food and water intake. After 6 weeks the animals were submitted to a grip strength test and sacrificed for specimen collection. Skin samples were analyzed histologically and for expression of NF-κB-regulated genes Bcl2 and Bcl2l1. Gastrocnemius muscles were weighted and analyzed for expression of NF-κB subunits p50, p52, p65, and Rel-B. DMAPT reduced the incidence of epidermal dysplasia (18.2% versus 33.3% in HPV16+/− untreated mice). This was associated with reduced expression of Bcl2 and Bcl2l1 (p = .0003 and p = .0014, respectively) and reduced neutrophilic infiltration (p = .0339). Treated mice also showed partially preserved bodyweight and strength, which were independent of the expression levels of NF-κB subunits in skeletal muscle.These results suggest that NF-κB inhibition may be a valid strategy against HPV-induced lesions in vivo and warrant further preclinical tests particularly in the set of combination therapies. In addition, the data may support the use of DMAPT to prevent wasting syndrome.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (SFRH/BD/135871/2018, UID/AGR/04033/2019, UID/EQU/00511/2019)
- European Regional Development Fund
This publication has 35 references indexed in Scilit:
- Targeting Nuclear Factor-Kappa B to Overcome Resistance to ChemotherapyFrontiers in Oncology, 2013
- The role of human papillomavirus in nongenital cancersCA: A Cancer Journal for Clinicians, 2012
- Inhibition of NF-κB and DNA double-strand break repair by DMAPT sensitizes non-small-cell lung cancers to X-raysFree Radical Biology and Medicine, 2011
- NFX1 Plays a Role in Human Papillomavirus Type 16 E6 Activation of NFκB ActivityJournal of Virology, 2010
- The Inflammation-Based Glasgow Prognostic ScorePredicts Survival in Patients With Cervical CancerInternational Journal of Gynecological Cancer, 2010
- Expression of NF-κB and IκB proteins in skeletal muscle of gastric cancer patientsEuropean Journal of Cancer, 2009
- Aminoparthenolides as novel anti-leukemic agents: Discovery of the NF-κB inhibitor, DMAPT (LC-1)Bioorganic & Medicinal Chemistry Letters, 2009
- An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cellsBlood, 2007
- Role of cysteine residues of p65/NF-κB on the inhibition by the sesquiterpene lactone parthenolide and N-ethyl maleimide, and on its transactivating potentialLife Sciences, 2004
- Transcriptional regulation of bcl-2 by nuclear factor κB and its significance in prostate cancerOncogene, 2001